In a small 34-person trial, an estriol-lactobacilli combination tablet produced greater improvements in vaginal tissue maturation and dryness than a polycarbophil moisturizer in women recovering from cervical cancer radiotherapy, though the clinical significance of sexual function gains remains unclear.
Radiation therapy for cervical cancer frequently triggers post-radiation vaginitis, a constellation of vaginal changes including tissue atrophy, dryness, inflammation, and reduced elasticity. These changes can persist for months or years after treatment concludes and substantially impact quality of life and sexual function. Current management typically relies on topical moisturizers or hormone-based treatments, but direct head-to-head comparisons of these approaches in this population have been limited.
This randomized controlled trial enrolled 34 women with Stage I-III cervical cancer who had completed pelvic radiotherapy and developed vaginal toxicity symptoms. Participants were randomly assigned to either an estriol-lactobacilli combination tablet (Gynoflor, taken for 4 weeks) or a polycarbophil-based moisturizer (Regelle, applied topically). The estriol component supplies localized estrogen to support epithelial tissue recovery, while the Lactobacilli strain was intended to restore vaginal microbiota. The polycarbophil moisturizer works through hydration and mechanical lubrication without hormonal or microbial components.
The primary outcome was change in vaginal maturation value, a microscopic measure of epithelial cell health. The estriol-lactobacilli group showed a median improvement of 19.65 points compared to 2.08 points in the moisturizer group (p = 0.035). This difference suggests the combination therapy more effectively restored vaginal epithelial maturation over the 4-week period. Secondary outcomes aligned with this finding: vaginal dryness and inflammation improved significantly in the estriol-lactobacilli group, though changes in vaginal pH, dyspareunia (painful intercourse), and vaginal pain were similar between groups.
Sexual function, measured by the Female Sexual Function Index, showed a median improvement of 6 points with estriol-lactobacilli versus 2 points with moisturizer (p = 0.01). However, absolute FSFI scores at week 4 were similar between groups, and the authors noted that the clinical significance of this relative improvement is uncertain. Both treatments were well tolerated with no serious adverse events reported. The authors emphasized that these findings are exploratory given the modest sample size, open-label design (participants knew which treatment they received), and short 4-week follow-up window.
If you're managing vaginal symptoms following cervical cancer radiotherapy, this study suggests that estriol-lactobacilli combination therapy may offer more substantial improvements in tissue repair metrics than standard polycarbophil moisturizers, at least over a one-month timeframe. The difference in vaginal maturation and dryness improvement appears meaningful, even if sexual function gains are modest in absolute terms.
However, several important caveats apply. The sample size is small, raising the possibility of chance findings. The open-label design means both participants and researchers knew who received which treatment, potentially introducing bias. Most critically, the study only tracked outcomes for 4 weeks, leaving questions about longer-term benefit, durability of improvements, and whether benefits persist or diminish after treatment stops.
For practical decision-making, this represents preliminary evidence that warrants larger, longer-duration trials. If you're considering treatment options for post-radiation vaginitis, discussion with your oncologist or gynecologist about both approaches remains essential, as individual response varies considerably and factors like previous hormone use, other medications, and personal preferences all influence the optimal choice.
| Attribute | Value |
|---|---|
| Study Type | Randomized Controlled Trial |
| Sample Size | 34 women |
| Duration | 4 weeks |
| Participants | Women with Stage I-III cervical cancer who completed pelvic radiotherapy and developed vaginal toxicity |
| Intervention Groups | Estriol-lactobacilli combination (n=17) vs. polycarbophil-based moisturizer (n=17) |
| Primary Outcome | Change in vaginal maturation value |
| Secondary Outcomes | Vaginal pH, vaginal toxicity symptoms, Female Sexual Function Index scores |
| Key Finding | Estriol-lactobacilli showed greater improvement in VMV (19.65 vs. 2.08 points, p=0.035) and vaginal dryness/inflammation |
| Evidence Tier | B tier (small RCT, short follow-up, open-label design) |
| Journal | The Journal of Obstetrics and Gynaecology Research |
| Registry | Thai Clinical Trials Registry: TCTR2024051001 |
Thongdee P, et al. Effects of Estriol-Lactobacilli Combination Versus Polycarbophil-Based Vaginal Moisturizer on Post-Radiation Vaginitis in Women With Cervical Cancer: A Randomized Controlled Trial. The Journal of Obstetrics and Gynaecology Research. 2024. PMID: 42836699
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.